VO-Ohpic trihydrate
Based on 38 publication(s) in Google Scholar
VO-Ohpic trihydrate is a highly potent inhibitor of PTEN with an IC50 of 46±10 nM.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- CAS No.: 476310-60-8
- Formule: C12H16N2O11V
- Masse moléculaire:415.20
-
Stockage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
-
Solvant et solubilité
- Protocole
- Pureté et documentation
- Références
-
Help & FAQs
-
PI3K/Akt/mTOR Compound Library
HY-L015
-
Stem Cell Signaling Compound Library
HY-L017
-
Anti-Cancer Compound Library
HY-L025
-
Autophagy Compound Library
HY-L029
-
Anti-Aging Compound Library
HY-L034
-
Oxygen Sensing Compound Library
HY-L045
-
Glycolysis Compound Library
HY-L058
-
Cytoskeleton Compound Library
HY-L060
-
Anti-Pancreatic Cancer Compound Library
HY-L077
-
Anti-Cancer Metabolism Compound Library
HY-L083
-
Glucose Metabolism Compound Library
HY-L092
-
Targeted Diversity Library
HY-L099
-
Antidepressant Compound Library
HY-L108
-
Pain-Related Compound Library
HY-L139
-
Cell Death Library
HY-L162
-
Bioactive Compound Library Max
HY-L181
-
Anti-Aging Compound Library Mini
HY-L034M
-
Bioactive Compound Library
HY-L001
-
High-Throughput Bioactive Compound Library
HY-L205
Publications Citing Use of MedChemExpress (MCE) VO-Ohpic trihydrate
More- Cell Stem Cell. 2022 Apr 7;29(4):545-558.e13. [Abstract]
- Bone Res. 2018 Nov 10;6:32. [Abstract]
- J Adv Res. 2025 Aug:74:589-607. [Abstract]
- Redox Biol. 2024 May 17:73:103200. [Abstract]
- Redox Biol. 2019 Jan;20:390-401. [Abstract]
- J Nanobiotechnology. 2025 May 25;23(1):376. [Abstract]
- Theranostics. 2019 Jul 9;9(16):4764-4778. [Abstract]
- Theranostics. 2019 Jul 9;9(18):5200-5213. [Abstract]
- Cell Death Dis. 2026 Jan 9;17(1):17. [Abstract]
- Cell Death Dis. 2025 Aug 7;16(1):595. [Abstract]
- Environ Sci Technol. 2020 Sep 1;54(17):10783-10796. [Abstract]
- Cell Death Dis. 2019 May; 10(5): 329. [Abstract]
- Phytomedicine. 2023 Dec:121:155117. [Abstract]
- Int J Mol Med. 2021 Jun;47(6):109. [Abstract]
- Clin Transl Med. 2022 Sep;12(9):e1061. [Abstract]
- Clin Transl Med. 2020 Dec;10(8):e240. [Abstract]
- Stem Cell Res Ther. 2019 Jul 29;10(1):217. [Abstract]
- Transl Psychiatry. 2021 Mar 26;11(1):185. [Abstract]
- Biochem Pharmacol. 2020 Jan;171:113715. [Abstract]
- Biochem Pharmacol. 2019 Oct:168:82-90. [Abstract]
- Commun Biol. 2026 Jan 23;9(1):311. [Abstract]
- Cell Biol Toxicol. 2025 Feb 27;41(1):53. [Abstract]
- Int J Mol Sci. 2023 Jun 9;24(12):9954. [Abstract]
- Int Immunopharmacol. 2022 Feb:103:107840. [Abstract]
- Mol Med Rep. 2022 Jul;26(1):246. [Abstract]
- Biochim Biophys Acta Mol Basis Dis. 2022 Jan 1;1868(1):166292. [Abstract]
- Mol Med Rep. 2018 Dec;18(6):5489-5501. [Abstract]
- Mol Cell Biochem. 2026 May;481(5):2119-2137. [Abstract]
- J Cell Mol Med. 2019 Nov;23(11):7535-7544. [Abstract]
- iScience. 2024 Jun 19;27(7):110306. [Abstract]
- Mol Nutr Food Res. 2019 Dec;63(24):e1900418. [Abstract]
- BMC Cancer. 2019 Apr 25;19(1):391. [Abstract]
- Funct Integr Genomics. 2024 Apr 3;24(2):71. [Abstract]
- Cancer Med. 2019 Aug;8(9):4265-4277. [Abstract]
- Mol Vis. 2018 Jul 23:24:485-494. [Abstract]
- Res Sq. 2026 Apr 30.
- SSRN. 2023 Jul 17.
- Eur Rev Med Pharmacol Sci. 2019 May;23(10):4406-4413. [Abstract]
Customer Validation & Images
-
WB
-
WB
-
WB
-
WB
-
WB
Activité biologique
IC50: 46±10 nM (PTEN)[1]
VO-OHpic with two OHpic ligands and an oxo ligand is a sterically demanding molecule, and one will therefore expect that binds substrate will affect the subsequent binding of the inhibitor due to steric hindrance. VO-OHpic significantly inhibits PTEN activity in low nanomolar concentrations (IC50, 46±10 nM), which is in agreement with the previously determined potency (IC50, 35±2 nM) in a PIP3-based assay. The inhibition constants Kic and Kiu are determined to be 27±6 and 45±11 nM, respectively[1]. VO-OHpic is an encouragingly specific and potent PTEN inhibitor. VO-OHpic is the most potent inhibitor (IC50=35 nM) of the PTEN lipid phosphatase activity[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
CAS No. 476310-60-8
-
Appearance Solid
-
Masse moléculaire 415.20
-
Formule C12H16N2O11V
-
Color Light green to green
-
SMILES
O[V+2]([N]1=CC=CC(O)=C1C2=O)([O-]2)([O-]C3=CC=CN=C3C4=O)([O-]4)=O.[H+].[3H2O]
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Publications (38)
-
Journal Impact Factor
-
Most Recent
-
Cell Stem Cell
A small-molecule cocktail promotes mammalian cardiomyocyte proliferation and heart regeneration. [Abstract]2022 Apr 7;29(4):545-558.e13. PMID: 35395187 -
Bone Res
NUMB maintains bone mass by promoting degradation of PTEN and GLI1 via ubiquitination in osteoblasts. [Abstract]2018 Nov 10;6:32. PMID: 30455992 -
J Adv Res
Salidroside sensitizes Triple-negative breast cancer to ferroptosis by SCD1-mediated lipogenesis and NCOA4-mediated ferritinophagy. [Abstract]2025 Aug:74:589-607. PMID: 39353532 -
Redox Biol
ARID3A enhances chemoresistance of pancreatic cancer via inhibiting PTEN-induced ferroptosis. [Abstract]2024 May 17:73:103200. PMID: 38781729 -
Redox Biol
Resveratrol as a new inhibitor of immunoproteasome prevents PTEN degradation and attenuates cardiac hypertrophy after pressure overload. [Abstract]2019 Jan;20:390-401. PMID: 30412827
VO-Ohpic trihydrate purchased from MedChemExpress. Usage Cited in: Redox Biol. 2019 Jan;20:390-401. [Abstract]
Western analysis of related genes expression in mice with the treatment of TAC, TAC+RES, and TAC+RES+VO-Ophic.
VO-Ohpic trihydrate purchased from MedChemExpress. Usage Cited in: Redox Biol. 2019 Jan;20:390-401. [Abstract]
Immunoblotting analysis show that RES treatment markedly inhibited Ang II-induced degradation of PTEN, activation of AKT and mTOR and inactivation of AMPK, but this effect is reversed by VO-OHpic.
VO-Ohpic trihydrate purchased from MedChemExpress. Usage Cited in: Redox Biol. 2019 Jan;20:390-401. [Abstract]
Immunoblotting analysis show that RES treatment markedly inhibited Ang II-induced degradation of PTEN, activation of AKT and mTOR and inactivation of AMPK, but this effect is reversed by VO-OHpic.
-
J Nanobiotechnology
An orally-administered nanotherapeutics with gold nanospheres supplying for rheumatoid arthritis therapy by re-shaping gut microbial tryptophan metabolism. [Abstract]2025 May 25;23(1):376. PMID: 40414887 -
Theranostics
Embryonic Stem Cells Modulate the Cancer-Permissive Microenvironment of Human Uveal Melanoma. [Abstract]2019 Jul 9;9(16):4764-4778. PMID: 31367256 -
Theranostics
Spontaneous evolution of human skin fibroblasts into wound-healing keratinocyte-like cells. [Abstract]2019 Jul 9;9(18):5200-5213. PMID: 31410210 -
Cell Death Dis
ZC3H15 regulates the ubiquitination of PTEN via recruitment of TRIM56 and promotes malignant progression of non-small cell lung cancer. [Abstract]2026 Jan 9;17(1):17. PMID: 41513632 -
Cell Death Dis
Activation of AKT via a dual mechanism enhances the susceptibility of melanoma cells to glucose deprivation. [Abstract]2025 Aug 7;16(1):595. PMID: 40774947 -
Environ Sci Technol
Tris(1,3-dichloro-2-propyl)phosphate Reduces the Lifespan via Activation of an Unconventional Insulin/Insulin-Like Growth Factor-1 Signaling Pathway. [Abstract]2020 Sep 1;54(17):10783-10796. PMID: 32786597 -
Cell Death Dis
S-nitrosylation of the Peroxiredoxin-2 promotes S-nitrosoglutathione-mediated lung cancer cells apoptosis via AMPK-SIRT1 pathway. [Abstract]2019 May; 10(5): 329. PMID: 30988280 -
Phytomedicine
Isovitexin alleviates hepatic fibrosis by regulating miR-21-mediated PI3K/Akt signaling and glutathione metabolic pathway: based on transcriptomics and metabolomics. [Abstract]2023 Dec:121:155117. PMID: 37820467 -
Int J Mol Med
Upregulation of NFKBIZ affects bladder cancer progression via the PTEN/PI3K/Akt signaling pathway. [Abstract]2021 Jun;47(6):109. PMID: 33907827 -
Clin Transl Med
PARK7 deficiency inhibits fatty acid β-oxidation via PTEN to delay liver regeneration after hepatectomy. [Abstract]2022 Sep;12(9):e1061. PMID: 36149763 -
Clin Transl Med
A selected small molecule prevents inflammatory osteolysis through restraining osteoclastogenesis by modulating PTEN activity. [Abstract]2020 Dec;10(8):e240. PMID: 33377656 -
Stem Cell Res Ther
Mouse embryonic palatal mesenchymal cells maintain stemness through the PTEN-Akt-mTOR autophagic pathway. [Abstract]2019 Jul 29;10(1):217. PMID: 31358051
VO-Ohpic trihydrate purchased from MedChemExpress. Usage Cited in: Stem Cell Res Ther. 2019 Jul 29;10(1):217. [Abstract]
Western blot showing the levels of phosphorylated and non-phosphorylated PTEN, AKT, and mTOR proteins before and after VO-OHpic trihydrate treatment.
-
Transl Psychiatry
2021 Mar 26;11(1):185. PMID: 33771972 -
Biochem Pharmacol
Catalpol suppresses osteoclastogenesis and attenuates osteoclast-derived bone resorption by modulating PTEN activity. [Abstract]2020 Jan;171:113715. PMID: 31751538 -
Biochem Pharmacol
2,5-Dimethylcelecoxib prevents isoprenaline-induced cardiomyocyte hypertrophy and cardiac fibroblast activation by inhibiting Akt-mediated GSK-3 phosphorylation. [Abstract]2019 Oct:168:82-90. PMID: 31229551 -
Commun Biol
DTX1-mediated degradation of TUBB3 in Kupffer cells mitigates hepatocellular carcinoma progression by regulating M1/M2 polarization. [Abstract]2026 Jan 23;9(1):311. PMID: 41577987 -
Cell Biol Toxicol
Glycolysis regulates palatal mesenchyme proliferation through Pten-Glut1 axis via Pten classical and non-classical pathways. [Abstract]2025 Feb 27;41(1):53. PMID: 40014184 -
Int J Mol Sci
PTEN Inhibitor Treatment Lowers Muscle Plasma Membrane Damage and Enhances Muscle ECM Homeostasis after High-Intensity Eccentric Exercise in Mice. [Abstract]2023 Jun 9;24(12):9954. PMID: 37373102 -
Int Immunopharmacol
USP20 mitigates ischemic stroke in mice by suppressing neuroinflammation and neuron death via regulating PTEN signal. [Abstract]2022 Feb:103:107840. PMID: 34953448 -
Mol Med Rep
LncRNA LINC00961 regulates endothelial‑mesenchymal transition via the PTEN‑PI3K‑AKT pathway. [Abstract]2022 Jul;26(1):246. PMID: 35656895 -
Biochim Biophys Acta Mol Basis Dis
Mycobacterium tuberculosis ESAT6 modulates host innate immunity by downregulating miR-222-3p target PTEN. [Abstract]2022 Jan 1;1868(1):166292. PMID: 34710568 -
Mol Med Rep
miR‑371b‑5p inhibits endothelial cell apoptosis in monocrotaline‑induced pulmonary arterial hypertension via PTEN/PI3K/Akt signaling pathways. [Abstract]2018 Dec;18(6):5489-5501. PMID: 30387816 -
Mol Cell Biochem
S-equol promotes ferroptosis in triple negative breast cancer by coordinating NCOA4-mediated ferritinophagy and PPARγ-mediated lipid metabolism. [Abstract]2026 May;481(5):2119-2137. PMID: 41925800 -
J Cell Mol Med
Aspirin inhibits adipogenesis of tendon stem cells and lipids accumulation in rat injury tendon through regulating PTEN/PI3K/AKT signalling. [Abstract]2019 Nov;23(11):7535-7544. PMID: 31557405 -
iScience
Epidermal growth factor augments the self-renewal capacity of aged hematopoietic stem cells. [Abstract]2024 Jun 19;27(7):110306. PMID: 39055915 -
Mol Nutr Food Res
Resveratrol Attenuates Pressure Overload-Induced Cardiac Fibrosis and Diastolic Dysfunction via PTEN/AKT/Smad2/3 and NF-κB Signaling Pathways. [Abstract]2019 Dec;63(24):e1900418. PMID: 31655498 -
BMC Cancer
Numb inhibits epithelial-mesenchymal transition via RBP-Jκ-dependent Notch1/PTEN/FAK signaling pathway in tongue cancer. [Abstract]2019 Apr 25;19(1):391. PMID: 31023264 -
Funct Integr Genomics
MATN2 overexpression suppresses tumor growth in ovarian cancer via PTEN/PI3K/AKT pathway. [Abstract]2024 Apr 3;24(2):71. PMID: 38568332 -
Cancer Med
Embryonic stem cell microenvironment suppresses the malignancy of cutaneous melanoma cells by down-regulating PI3K/AKT pathway. [Abstract]2019 Aug;8(9):4265-4277. PMID: 31173492 -
Mol Vis
2018 Jul 23:24:485-494. PMID: 30967746
VO-Ohpic trihydrate purchased from MedChemExpress. Usage Cited in: Mol Vis. 2018 Jul 23:24:485-494. [Abstract]
The miR-21 inhibitor promotes the expression of the PTEN protein and inhibits the expression of p-AKT, and VO-Ohpic trihydrate reverses the effect.
-
-
-
Eur Rev Med Pharmacol Sci
2019 May;23(10):4406-4413. PMID: 31173315
Solvant et solubilité
DMSO : ≥ 50 mg/mL (120.42 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
H2O : < 0.1 mg/mL (insoluble)
* "≥" means soluble, but saturation unknown.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (6.02 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (6.02 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Protocole
VO-OHpic is dissolved in DMSO (100 μM) and diluted further to the required concentration with 1% DMSO. For inhibition studies, PTEN is preincubated with VO-OHpic at RT for 10 min before substrate is added to initialise the reaction. Background absorbance (malachite green assay) and fluorescence (OMFP assay) are determined with VO-OHpic in assay buffer and corrected in the data analysis[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Mice[3]
The experiment is performed with male C57BL6 mice. Briefly, mice are anesthetized with pentobarbital (70 mg/kg). The left coronary artery is occluded about 1-2 mm below the left auricle. Reperfusion is accomplished by loosening the ligature. The PTEN inhibitor VO-OHpic is administered by intra-peritoneal injection at the dosage of 10 μg/kg once 30 min before ischemia. Saline is used as control. At the end of the experiment, the animals are euthanized by transecting the aorta and removing the heart for infarct size determination.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Pureté et documentation
-
Fiche technique (287 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
-
Instruction de manipulation (2659 KB)
Références
[1]. Mak LH, et al. Characterisation of the PTEN inhibitor VO-OHpic. J Chem Biol. 2010 Oct;3(4):157-63. [Content Brief]
[2]. Rosivatz, E, et al. A small molecule inhibitor for phosphatase and tensin homologue deleted on chromosome 10 (PTEN). ACS Chem Biol. 2006 Dec 15;1(12):780-90. [Content Brief]
[3]. Zu L, et al. PTEN inhibitors cause a negative inotropic and chronotropic effect in mice. Eur J Pharmacol. 2011 Jan 10;650(1):298-302. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.4085 mL | 12.0424 mL | 24.0848 mL | 60.2119 mL |
| 5 mM | 0.4817 mL | 2.4085 mL | 4.8170 mL | 12.0424 mL | |
| 10 mM | 0.2408 mL | 1.2042 mL | 2.4085 mL | 6.0212 mL | |
| 15 mM | 0.1606 mL | 0.8028 mL | 1.6057 mL | 4.0141 mL | |
| 20 mM | 0.1204 mL | 0.6021 mL | 1.2042 mL | 3.0106 mL | |
| 25 mM | 0.0963 mL | 0.4817 mL | 0.9634 mL | 2.4085 mL | |
| 30 mM | 0.0803 mL | 0.4014 mL | 0.8028 mL | 2.0071 mL | |
| 40 mM | 0.0602 mL | 0.3011 mL | 0.6021 mL | 1.5053 mL | |
| 50 mM | 0.0482 mL | 0.2408 mL | 0.4817 mL | 1.2042 mL | |
| 60 mM | 0.0401 mL | 0.2007 mL | 0.4014 mL | 1.0035 mL | |
| 80 mM | 0.0301 mL | 0.1505 mL | 0.3011 mL | 0.7526 mL | |
| 100 mM | 0.0241 mL | 0.1204 mL | 0.2408 mL | 0.6021 mL |
VO-Ohpic trihydrate Related Classifications
HY-13074 Related Classifications
Powered by Bioz